海西新药(02637)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02637 海西新药

未开盘 07-02 16:08:21

189.000

+9.000

+5.00%

最高205.800	最低188.900	成交量27.36万
今开189.600	昨收180.000	日振幅9.39%
总市值148.76亿	流通市值148.76亿	总股本7,871万
成交额5,329万	换手率0.35%	流通股本7,871万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02637","market":"HK","secType":"STK","nameCN":"海西新药","latestPrice":189,"timestamp":1782979701006,"preClose":180,"halted":0,"volume":273600,"delay":0,"changeRate":0.05,"floatShares":78707270,"shares":78707270,"eps":2.9458782655069915,"marketStatus":"未开盘","change":9,"latestTime":"07-02 16:08:21","open":189.6,"high":205.8,"low":188.9,"amount":53293487,"amplitude":0.093889,"askPrice":190.4,"askSize":800,"bidPrice":189,"bidSize":2550,"shortable":3,"etf":0,"ttmEps":2.87656348278918,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783042200000},"marketStatusCode":0,"adr":0,"listingDate":1760889600000,"exchange":"SEHK","adjPreClose":180,"openAndCloseTimeList":[[1782955800000,1782964800000],[1782968400000,1782979200000]],"volumeRatio":1.5013169453473736,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02637","defaultTab":"news","newsList":[{"id":"2647475483","title":"创新药概念全线扬升 晶泰控股(02228)涨逾14% 机构指创新药仍为行业核心增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2647475483","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647475483?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:33","pubTimestamp":1782700428,"startTime":"0","endTime":"0","summary":"消息面上，华鑫证券新近研究表示，自2015年创新药审批改革开始，创新药逐步成为医药行业的核心增量。以恒瑞医药为代表的创新药企业，创新药的收入比重持续提升。6月份以来，已有药明康德等企业开始公告回购或增持方案，逐步扭转市场对医药行业的信心。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984679","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530","LU1328277881.USD","IE00B5MMRT66.SGD","LU0348735423.USD","09995","LU0348783233.USD","LU0540923850.HKD","LU2476274308.USD","LU0417516902.SGD","LU0348825331.USD","LU1720050803.USD","LU1226287529.USD","IE00BZ08YS42.EUR","LU0348827113.USD","LU1969619763.USD","LU1993786604.SGD","LU0140636845.USD","LU0634319403.HKD","06855","LU2476274720.SGD","09926","01093","159992","02157","LU1961090484.USD","LU1008478684.HKD","BK1583","LU1226287792.SGD","LU0067412154.USD","IE00B543WZ88.USD","LU0072913022.USD","LU0348767384.USD","02637","BK1141","LU1226288253.USD","LU0348784397.USD","IE00BZ08YR35.GBP","LU1951186391.HKD","02162","BK1574","LU0417516571.SGD","LU1960683339.HKD","06978","09969","LU0326950275.SGD","LU0880133367.SGD","02228","LU0315179316.USD","LU0348766576.USD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645201476","title":"海西新药(02637)存仓市值总计17.01亿港元 公司股东将988.26万股股票存入招银国际证券","url":"https://stock-news.laohu8.com/highlight/detail?id=2645201476","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645201476?lang=zh_cn&edition=full","pubTime":"2026-06-22 08:32","pubTimestamp":1782088358,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，6月18日，海西新药(02637)出现仓位异动，存仓市值总计17.01亿港元，占比12.60%。该公司股东将988.26万股股票存入招银国际证券，持股比例增加12.56%。此前海西新药公布2025年业绩，收益为约5.82亿元，同比增长24.79%;净利约1.77亿元，同比增长30.09%;每股盈利为2.55元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456678.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","161027","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643571732","title":"【券商聚焦】中信建投证券首予海西新药“买入”评级 指其创新管线进展顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2643571732","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643571732?lang=zh_cn&edition=full","pubTime":"2026-06-16 15:47","pubTimestamp":1781596045,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报指，海西新药 2025年业绩符合预期，营收达5.82亿元，同比增长24.8%，收入增长主因药品市场份额持续提升。净利润1.77亿元，同比增长30.1%。中信建投证券首次覆盖给予“买入”评级，预计公司2026至2028年收入分别为7.10亿元、8.53亿元、10.15亿元。风险包括新药研发不确定性及仿制药降价超预期带来的商业化压力。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983895","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643221793","title":"海西新药(02637.HK)首次覆盖：眼底病赛道大年 HXP056有望改写治疗范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2643221793","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643221793?lang=zh_cn&edition=full","pubTime":"2026-06-14 01:17","pubTimestamp":1781371022,"startTime":"0","endTime":"0","summary":"　　公司首创口服眼底病重磅药物：HXP056。2020-2024年全球品牌抗VEGF药物的总销售额呈现逐年递增趋势，2024年全球销售额近150亿美金，2025年因阿柏西普仿制药竞争整体市场首次出现下滑。HXP056利用MultiSel-Opt平台实现血视网膜屏障高穿透、系统暴露快速清除，临床前研究显示HXP056在小鼠和大鼠中，能够穿透BRB，眼球分布高，眼球中半衰期长，只在局部发挥疗效。　　HXP056临床进展顺利，I/II期数据积极。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260614/32279024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642941450","title":"招银国际：首予海西新药(02637)“买入”评级 目标价280港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2642941450","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642941450?lang=zh_cn&edition=full","pubTime":"2026-06-10 11:02","pubTimestamp":1781060558,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，海西新药(02637)是一家集研发、生产与销售于一体的创新型商业化药企，拥有15款获批仿制药及4款在研创新药，其中HXP056有望成为全球首款眼底病口服疗法，首次覆盖给予“买入”评级，目标价280港元。该行指，仿制药业务作为现金牛为创新提供持续资金支持，截至2025年底，公司有15款仿制药获批，其中3款市场份额居前二，现金流充沛，预计2026年净利同比增长18.9%至2.105亿元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02637","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134415369","title":"海西新药5月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1134415369","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134415369?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:37","pubTimestamp":1780562259,"startTime":"0","endTime":"0","summary":"福建海西新药创制股份有限公司于2026年6月4日公布截至2026年5月31日的股份变动月报表。公告显示，公司本月底法定注册股本合计78,707,270股，面值每股人民币1元，总额为人民币78,707,270元，与上月底保持一致。与此同时，海西新药于本月底的已发行股份总数为78,707,270股，无库存股份，报告期内未有新增发行、购回或注销股份等变动。公司声明将继续遵守香港联交所《上市规则》及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638505405","title":"海西新药(02637)：康心汕获选为董事会董事长","url":"https://stock-news.laohu8.com/highlight/detail?id=2638505405","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638505405?lang=zh_cn&edition=full","pubTime":"2026-05-27 17:38","pubTimestamp":1779874691,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海西新药(02637)发布公告，陈枢仪博士及龚为民先生于股东周年大会结束后退任董事会董事。于股东周年大会上，李俊青先生获选任为执行董事，林斌先生获选任为独立非执行董事，任期为三年，由股东周年大会结束起，直至本公司2029年举行的股东周年大会结束为止。于董事会会议上，董事会选举康心汕为第二届董事会董事长，任期三年，自董事会会议召开之日起算。于董事会会议上，董事会亦已委任康心汕为本公司总经理;Feng Yan女士为本公司副总经理;Chen Guangming博士为本公司副总经理;张明强博士为本公司副总经理;及张俊环女士为本公司董事会秘书、财务总监。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446647.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160591525","title":"异动解读｜海西新药盘中上涨5.37%，回调后复苏延续受强劲年报及券商覆盖支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=1160591525","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160591525?lang=zh_cn&edition=full","pubTime":"2026-05-20 14:42","pubTimestamp":1779259338,"startTime":"0","endTime":"0","summary":"5月20日，海西新药盘中上涨5.37%，报247.4港元/股，成交额2868.19万港元。该股延续近日反弹走势，在5月13日至15日回调充分消化获利盘后重拾升势。消息面上，公司年报显示营业收入5.82亿元，同比增长24.79%；归母净利润1.77亿元，同比增长30.09%；毛利率提升至83.38%。国海证券、华源证券、申万宏源等多家券商给予\"买入\"评级，目标价区间298至339港元，较当前股价仍有较大上行空间。值得注意的是，制药板块今日整体偏弱，海西新药逆势走强。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178209460","title":"海西新药4月股份变动月报表披露，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1178209460","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178209460?lang=zh_cn&edition=full","pubTime":"2026-05-07 17:48","pubTimestamp":1778147291,"startTime":"0","endTime":"0","summary":"5月7日，福建海西新药创制股份有限公司发布截至2026年4月30日的股份变动月报表。公告显示，公司于报告期内的已发行股本和注册股本均无任何增减变化，股本状况保持稳定。福建海西新药创制股份有限公司在报告期内的普通股H股股份总数维持在78,707,270股，公司注册股本合计人民币78,707,270元，面值每股人民币1元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182854792","title":"异动解读 | 海西新药盘中大涨5.74%，年报业绩超预期叠加券商首次覆盖提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1182854792","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182854792?lang=zh_cn&edition=full","pubTime":"2026-05-05 09:38","pubTimestamp":1777945135,"startTime":"0","endTime":"0","summary":"海西新药今日盘中大涨5.74%，引起了市场的广泛关注。消息面上，公司近日披露的2025年度报告显示，其营业收入和归母净利润均实现显著增长，业绩表现超出市场预期。与此同时，华源证券首次覆盖该股并给予“买入”评级，指出公司正升级为“仿创一体化”药企，其创新药HXP056为潜在首批口服治疗wAMD/DME/RVO的药物，有望打开中长期估值空间。华源证券在报告中强调，海西新药的战略转型和研发管线进展，特别是HXP056的潜力，是支撑其“买入”评级和未来估值提升的关键因素。市场分析认为，今日的股价反弹反映了投资者对公司基本面利好的重新定价。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172614044","title":"异动解读 | 海西新药盘中大跌8.35%，解禁抛压与高位回落致股价承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1172614044","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172614044?lang=zh_cn&edition=full","pubTime":"2026-05-04 09:56","pubTimestamp":1777859794,"startTime":"0","endTime":"0","summary":"海西新药(02637)今日盘中大跌8.35%，引起了市场的广泛关注。消息面上，该股此前近一个月内股价实现翻倍，触及历史高点后曾单日暴跌逾25%，虽随后连续反弹，但整体仍处于高位震荡回落格局。此外，该股上市满半年迎来解禁，基石投资者持有198.17万股，占总股本2.52%，短期抛压仍需消化。前期获利盘出逃叠加解禁压力，共同压制股价表现。当前成交额明显萎缩，市场观望情绪浓厚，股价在多重因素影响下持续调整。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632604150","title":"格隆汇个股放量排行榜 | 5月3日","url":"https://stock-news.laohu8.com/highlight/detail?id=2632604150","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632604150?lang=zh_cn&edition=full","pubTime":"2026-05-03 17:30","pubTimestamp":1777800604,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日天数智芯(09903)、上海实业控股(00363)、网易-S(09999)、永达汽车(03669)、永利澳门(01128)、中国铁建(01186)、中国信达(01359)、力量发展(01277)、中国光大银行(06818)、汽车街(02443)、中国白银集团(00815)、赛力斯(09927)、太古股份公司A(00019)、中信国际电讯(01883)、华星控股(08","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/03173056983654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["00568","02583","02656","01643","09927","01429","02637","06110","02516","00189","00501","01211","02655","00558","01765","00259","09903","00178","00148","00800","02408","00019","00815","02595","01458","01347","00981","02676","02579","00709","00880","02687","01833","02276","09999","02443","00780","00220","00719","00363","00168","06938","00133","02489","09990","00909","00659","06979","00650","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632158966","title":"格隆汇个股放量排行榜 | 5月1日","url":"https://stock-news.laohu8.com/highlight/detail?id=2632158966","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632158966?lang=zh_cn&edition=full","pubTime":"2026-05-01 17:30","pubTimestamp":1777627804,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日天数智芯(09903)、上海实业控股(00363)、网易-S(09999)、永达汽车(03669)、永利澳门(01128)、中国铁建(01186)、中国信达(01359)、力量发展(01277)、中国光大银行(06818)、汽车街(02443)、中国白银集团(00815)、赛力斯(09927)、太古股份公司A(00019)、中信国际电讯(01883)、华星控股(08","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/01173056970876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02276","00719","02637","02656","02676","00178","01211","00133","00189","02489","02516","00909","02655","06110","00363","00650","02579","00259","01429","09999","00880","01458","06979","09927","00019","00709","01833","02583","00558","00815","00168","00800","00501","00780","01347","02595","02443","00659","02408","01643","09903","00220","09990","00981","06821","01765","02687","00568","00148","06938"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2631468969","title":"【券商聚焦】华源证券首予海西新药(02637)“买入”评级 指创新药HXP056有望打开估值空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2631468969","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631468969?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:45","pubTimestamp":1777538722,"startTime":"0","endTime":"0","summary":"报告指，公司正从传统仿制药商业化平台升级为“仿创一体化”药企，仿制药业务提供稳定现金流，创新管线HXP056有望打开中长期估值上限。业务亮点包括：1.创新药HXP056：为潜在首批口服治疗wAMD/DME/RVO的药物，全球尚无已获批的wAMD口服制剂。2025年仿制药收入结构中，海慧通占比50.29%，安必力占比27.94%。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/ZmY0OWUwYjc0ZDYzZDFkYzRkNWJlMTY3NjE5MjUxNjU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZmY0OWUwYjc0ZDYzZDFkYzRkNWJlMTY3NjE5MjUxNjU=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980352","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","159992","06978","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142571820","title":"异动解读 | 海西新药盘中大涨9.54%，股份激励计划与机构看好推动股价反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1142571820","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142571820?lang=zh_cn&edition=full","pubTime":"2026-04-30 09:38","pubTimestamp":1777513130,"startTime":"0","endTime":"0","summary":"海西新药今日盘中大涨9.54%，引起了市场的广泛关注。消息面上，公司董事会决议建议采纳H股股份激励计划，旨在建立长效激励机制，将股东、公司及员工利益紧密结合，此举增强了市场对公司未来发展的信心。同时，申万宏源近期首次覆盖该股并给予“买入”评级，目标价298.28港元，指出公司仿制药业务稳健，创新药管线进展积极。此外，该股此前经历了一段回调，此次上涨也包含了技术性反弹的因素。股份激励计划的落地与机构看好其基本面，共同推动了股价的强劲表现。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144056621","title":"海西新药(02637)2025年收入与利润稳步增长，持续加码研发推进创新药管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1144056621","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144056621?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:59","pubTimestamp":1777467566,"startTime":"0","endTime":"0","summary":"海西新药于2025年度实现主要经营指标的多重增长。据年报显示，集团期内收入达到5.82亿元人民币，其中15款获国家药品监督管理部门批准上市的仿制药有力支撑业绩。2025年集团净利润为1.77亿元人民币，同比上升30.1%，毛利达4.86亿元人民币，同比增长25.4%，毛利率水平维持在83.4%的较高位置，表现出良好的盈利能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海西新药(02637)2025年收入与利润稳步增长，持续加码研发推进创新药管线","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631520514","title":"海西新药(02637)建议采纳H股股份激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2631520514","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631520514?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:49","pubTimestamp":1777466974,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海西新药(02637)发布公告，于2026年4月29日，董事会已决议建议采纳一项适用于公司H股的股份激励计划。股份激励计划旨在进一步建立、健全公司的长效激励机制，充分调动核心员工的积极性，有效地将公司股东利益、公司利益及员工个人利益结合在一起，使各方共同推动公司的持续健康发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436553.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163511873","title":"异动解读 | 海西新药盘中大涨7.66%，机构看好与创新药进展提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1163511873","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163511873?lang=zh_cn&edition=full","pubTime":"2026-04-29 09:59","pubTimestamp":1777427999,"startTime":"0","endTime":"0","summary":"海西新药今日盘中大涨7.66%，引起了市场的广泛关注。消息面上，申万宏源近期首次覆盖海西新药并给予\"买入\"评级，目标价298.28港元。公司仿制药业务已连续5年实现盈利，营业收入达5.82亿元人民币，同比增长25%，净利润1.77亿元，同比增长30%。创新药方面，C019199即将进入III期临床阶段，HXP056有望迎来数据验证。此外，该股前一交易日曾一度跌超25%，由历史高点大幅回落，今日呈现技术性反弹。需关注的是，该股此前上市满半年迎来解禁，基石投资者持有198.17万股，占总股本2.52%，短期抛压仍需消化。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173921670","title":"异动解读 | 海西新药盘中大涨5.06%，券商首次覆盖叠加创新药管线催化推动股价走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1173921670","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173921670?lang=zh_cn&edition=full","pubTime":"2026-04-28 09:48","pubTimestamp":1777340905,"startTime":"0","endTime":"0","summary":"海西新药今日盘中大涨5.06%，引起了市场的广泛关注。消息面上，申万宏源近日首次覆盖海西新药并给予“买入”评级，目标价298.28港元。研报指出，公司仿制药业务已连续5年盈利，营业收入达5.82亿元人民币，同比增长25%，净利润1.77亿元，同比增长30%。此外，公司公告新一代原创创新药HXP056口服治疗眼底病I期临床数据显示良好安全性与耐受性，在wAMD患者中观察到眼底形态与视网膜功能初步改善，具有全球重磅大单品潜力；进度最快的C019199即将进入III期临床阶段。券商首次覆盖叠加创新药管线数据验证预期，共同推动了公司股价的强势表现。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630442356","title":"港股异动丨海西新药大涨近18%创新高，年内已累涨超105%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630442356","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630442356?lang=zh_cn&edition=full","pubTime":"2026-04-27 11:27","pubTimestamp":1777260422,"startTime":"0","endTime":"0","summary":"海西新药盘中一度大涨近18%，最高触及280港元，创下历史新高。该股年内已累计上涨超105%。　　消息面上，海西新药于上月底公布2025年业绩，收益约5.82亿元，同比增长24.79%；净利约1.77亿元，同比增长30.09%。　　另外，申万宏源近期研报首次覆盖海西新药，给予“买入”评级。该行指，在稳定且持续盈利后，公司大力推进创新药研发，进度最快的C019199即将进入III期临床阶段，具有全球重磅大单品潜力的HXP056有望迎来数据验证。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260427/32178800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1191","VXUS","02637","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hxpharma.com","stockEarnings":[{"period":"1week","weight":0.119},{"period":"1month","weight":-0.0531},{"period":"3month","weight":0.0696},{"period":"6month","weight":0.4329},{"period":"1year","weight":1.1875},{"period":"ytd","weight":0.3897}],"compareEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":-0.1146},{"period":"3month","weight":-0.0821},{"period":"6month","weight":-0.1247},{"period":"1year","weight":-0.0482},{"period":"ytd","weight":-0.1005}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"福建海西新药创制股份有限公司成立于2012年3月27日。公司是一家处于商业化阶段的制药公司,集研发、生产及销售能力于一体,具备在研创新药的管线。公司在中国最大、增长最快的治疗领域拥有多元化的产品组合及管线。截至最后实际可行日期,公司已商业化的产品组合主要包括用于消化系统疾病、心血管系统疾病、内分泌系统疾病、神经系统疾病及炎症疾病的仿制药。根据灼识咨询的资料,该等治疗领域占2023年中国医药销售总额的25%以上。公司的创新药管线专注于具有各种适应症的在研药物,包括一款潜在属同类首款的在研肿瘤药物、一款潜在用于治疗湿性年龄相关性黄斑变性(wAMD)╱糖尿病性黄斑水肿(DME)╱视网膜静脉阻塞(RVO)的首款口服药物及另外两款处于临床前阶段,用于治疗肿瘤及呼吸系统疾病的创新在研药物。公司所有在研创新药均由内部以专有方式开发及发展。","exchange":"SEHK","name":"海西新药","nameEN":"HAIXI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海西新药(02637)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海西新药(02637)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海西新药,02637,海西新药股票,海西新药股票老虎,海西新药股票老虎国际,海西新药行情,海西新药股票行情,海西新药股价,海西新药股市,海西新药股票价格,海西新药股票交易,海西新药股票购买,海西新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海西新药(02637)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海西新药(02637)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}